Want to see SE:CLBIO full AI Analyst Report?

Corline Biomedical AB (CLBIO) Price & Analysis

0 Followers

CLBIO Stock Chart & Stats

kr17.60

kr0.15(0.85%)

At close: Jul 27 4:00 PM EDT

kr17.60

kr0.15(0.85%)

Day’s Range― - ―

52-Week Rangekr13.95 - kr27.20

Previous CloseN/A

Volume165.00

Average Volume (3M)12.01K

Market Cap

kr385.46M

Enterprise Valuekr436.10

Total Cash (Recent Filing)kr32.99M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.36

Next Earnings

Nov 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.49

Shares Outstanding26,133,118

10 Day Avg. Volume12,703

30 Day Avg. Volume12,013

Financial Highlights & Ratios

PEG Ratio0.63

Price to Book (P/B)4.33

Price to Sales (P/S)53.02

P/FCF Ratio-22.87

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.7

Revenue Forecast (FY)kr41.80M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthStrong TTM revenue growth indicates increasing customer adoption of Corline’s blood-compatible technologies. Sustained commercial traction could support operating leverage and improve the path toward profitability if growth converts into higher-margin recurring sales.

Debt-Free Balance SheetA debt-free balance sheet limits leverage pressure, interest obligations, and refinancing risk. The sizable equity base provides financial resilience and flexibility to fund development while the company works toward improved profitability.

Proprietary Blood-Compatibility TechnologyCorline addresses a persistent clinical and engineering problem through specialized biomaterial and coating technologies. Proprietary solutions can support differentiation, recurring product demand, licensing opportunities, and partnerships across transplantation, devices, and advanced therapies.

Bears Say

Persistent Net LossesPersistent losses show that commercial growth has not yet translated into a self-sustaining earnings model. Continued negative margins could constrain reinvestment capacity and increase dependence on future financing unless scale and gross economics improve.

Ongoing Cash BurnSustained operating and free-cash-flow deficits indicate that the business consumes cash while pursuing growth. Without stronger operating performance, Corline may need external funding, creating dilution risk or limiting the pace of technology and commercial development.

Earnings VolatilityThe shift from profitability to substantial losses demonstrates limited earnings stability and makes future performance harder to forecast. Volatility may reflect uneven collaboration, product, or development revenue and reduces confidence in predictable operating leverage.

CLBIO FAQ

What was Corline Biomedical AB’s price range in the past 12 months?

Corline Biomedical AB lowest stock price was kr13.95 and its highest was kr27.20 in the past 12 months.

What is Corline Biomedical AB’s market cap?

Corline Biomedical AB’s market cap is kr385.46M.

When is Corline Biomedical AB’s upcoming earnings report date?

Corline Biomedical AB’s upcoming earnings report date is Nov 19, 2026 which is in 61 days.

How were Corline Biomedical AB’s earnings last quarter?

Corline Biomedical AB released its earnings results on Aug 21, 2026. The company reported -kr0.055 earnings per share for the quarter.

Is Corline Biomedical AB overvalued?

According to Wall Street analysts Corline Biomedical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Corline Biomedical AB pay dividends?

Corline Biomedical AB does not currently pay dividends.

What is Corline Biomedical AB’s EPS estimate?

Corline Biomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Corline Biomedical AB have?

Corline Biomedical AB has 26,133,118 shares outstanding.

What happened to Corline Biomedical AB’s price movement after its last earnings report?

Corline Biomedical AB reported an EPS of -kr0.055 in its last earnings report. Following the earnings report the stock price went up 0.833%.

Which hedge fund is a major shareholder of Corline Biomedical AB?

Currently, no hedge funds are holding shares in SE:CLBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Corline Biomedical AB

Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.